SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Oct 2014 07:00

RNS Number : 8130T
Victrex PLC
09 October 2014
 



 

 

 

 

9 October 2014

 

Victrex plc - Pre-close trading statement

 

"A strong finish to 2014 - growth momentum continues"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its pre-close trading statement for the financial year ended 30 September 2014, ahead of its preliminary results on Tuesday 9 December 2014.

 

Victrex delivered a strong finish to 2014, with the Group continuing its volume growth momentum from the first half year across our strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Full year Group sales volume of 3,551 tonnes increased by 22% (2013: 2,920 tonnes), with second half year sales volume of 1,967 tonnes increasing by 29% on last year (H2 2013: 1,528 tonnes). Although sales volumes were particularly strong, our profit expectations remain largely unchanged.

 

The strong volume performance in our Victrex Polymer Solutions (VPS) business reflects core growth and higher than expected volumes in the second half year from Consumer Electronics. Stripping out sales volumes across the entire Electronics segment, second half year sales volume increased by 6% on the prior year. Our higher margin Speciality Products business, including Aptiv film, again performed well during the year. With continued growth in Aptiv, we will bring an additional production line on stream during the first half of our new financial year.

 

In our higher margin Invibio medical business, full year revenue increased by 5% to £53.4m (2013: £50.8m), reflecting steady improvement in the Spine market. The focus for 2015 remains the roll-out of new products into the Spine market, with regulatory applications lodged in the US and Europe for the innovative PEEK-OPTIMA® HA-Enhanced product, which enhances bone-on-growth. Pending regulatory approval, adoption and roll-out will commence during the first half.

 

As we start our new financial year, our growth momentum remains positive. Although currency headwinds remain considerable in 2015, our forthcoming new PEEK and Aptiv film capacity, technical excellence and marketing know-how keep us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead / Rebecca Hall +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the strategic markets of Aerospace, Automotive, Electronics, Energy and Medical. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Visit www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Thursday 9 October 08.30 UK time. For dial in details contact Rebecca Hall at Pendomer on +44 (0) 203 603 5220 or Rebecca.Hall@pendomer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGBAUUPCGCR
Date   Source Headline
24th Jun 20249:44 amRNSHolding(s) in Company
14th Jun 20249:00 amRNSAdditional Listing
3rd Jun 20242:19 pmRNSBlock listing Interim Review
3rd Jun 20249:30 amRNSDirector/PDMR Shareholding
31st May 202411:23 amRNSTotal Voting Rights
23rd May 20247:00 amRNSSBTI approval of carbon reduction targets
15th May 20243:59 pmRNSDirector/PDMR Shareholding
14th May 20244:05 pmRNSDirector/PDMR Shareholding
13th May 20247:00 amRNSVictrex plc - Interim Results 2024
7th May 20243:25 pmRNSDirector Declaration
30th Apr 20242:54 pmRNSTotal Voting Rights
28th Mar 20249:56 amRNSTotal Voting Rights
15th Mar 20248:30 amRNSDirectorate Change
6th Mar 20242:06 pmRNSDirector/PDMR Shareholding
29th Feb 20249:36 amRNSTotal Voting Rights
21st Feb 20248:00 amRNSBlock listing Interim Review
9th Feb 202412:16 pmRNSResult of AGM
9th Feb 20247:00 amRNSAGM & Q1 Interim Management Statement
31st Jan 202412:26 pmRNSTotal Voting Rights
25th Jan 202410:57 amRNSHolding(s) in Company
9th Jan 202412:13 pmRNSAnnual Report & Accounts
29th Dec 20239:00 amRNSTotal Voting Rights
12th Dec 202310:21 amRNSDirector/PDMR Shareholding
5th Dec 20232:42 pmRNSDirector/PDMR Shareholding
5th Dec 20232:33 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSVictrex plc - Preliminary Results 2023
1st Dec 202310:41 amRNSBlock listing Interim Review
30th Nov 202311:10 amRNSTotal Voting Rights
3rd Nov 20231:31 pmRNSHolding(s) in Company
31st Oct 20239:36 amRNSTotal Voting Rights
19th Sep 20231:59 pmRNSDirector/PDMR Shareholding
8th Sep 20239:32 amRNSHolding(s) in Company
31st Aug 20239:30 amRNSTotal Voting Rights
23rd Aug 202310:52 amRNSHolding(s) in Company
17th Aug 20231:27 pmRNSDirector/PDMR Shareholding
31st Jul 20239:39 amRNSTotal Voting Rights
18th Jul 202311:51 amRNSDirector/PDMR Shareholding
13th Jul 20232:00 pmRNSAdditional Listing
6th Jul 20237:00 amRNSVictrex plc - Q3 Interim Management Statement
3rd Jul 20234:03 pmRNSHolding(s) in Company
30th Jun 20239:37 amRNSTotal Voting Rights
27th Jun 202310:08 amRNSDirector/PDMR Shareholding
19th Jun 20232:27 pmRNSDirector/PDMR Shareholding
14th Jun 20237:00 amRNSTrading Statement
1st Jun 202312:08 pmRNSBlock listing Interim Review
31st May 20239:52 amRNSTotal Voting Rights
17th May 202310:55 amRNSDirector/PDMR Shareholding
16th May 202310:03 amRNSDirector/PDMR Shareholding
12th May 202310:37 amRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.